Pre-made Olendalizumab benchmark antibody ( Whole mAb, anti-C5/CO5 therapeutic antibody, Anti-CPAMD4/ECLZB Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-395
Pre-Made Olendalizumab biosimilar, Whole mAb, Anti-C5/CO5 Antibody: Anti-CPAMD4/ECLZB therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Olendalizumab is a novel anti-inflammatory monoclonal antibody targeting complement protein C5a. Upon intravenous administration, anti-inflammatory antibody olendalizumab modulates the complement inflammatory pathway through binding to C5a.This inhibits C5a-mediated signal transduction, and results in the prevention and/or inhibition of both complement-mediated inflammation and cell destruction.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|List Price(In USD)
Size： 1mg | 10mg | 100mg
|Products Name (INN Index)
|Pre-Made Olendalizumab biosimilar, Whole mAb, Anti-C5/CO5 Antibody: Anti-CPAMD4/ECLZB therapeutic antibody
|Highest_Clin_Trial (Jan '20)
|100% SI Structure
|99% SI Structure
|95-98% SI Structure
|Antiphospholipid syndrome;Graft-versus-host disease